Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > I apologize
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(33)
•••
Comment by Inthepezon Aug 20, 2021 10:28am
94 Views
Post# 33739389

RE:RE:RE:RE:RE:RE:RE:RE:RE:I apologize

RE:RE:RE:RE:RE:RE:RE:RE:RE:I apologize Ok incel. Too much emotion is an incel pretending he owns a car that he didn’t pay for because random people on stockhouse trolled him. But you’re likely too stup!d to appreciate the irony lol!

The drug is too powerful. That’s never a bad thing. the value of Otena is there, it’s only delays at this point, so monetization will be delayed. 

Thanks for the lols incel 

Rarbar99 wrote:

Your problem is that you have too much emotion. As soon as you spot a bear you start getting angry and personal with them. This is why you’re a failed investor. You need to let that emotion go and just relax, it’s not that serious. You're like a little child who's angry I stole his toy.



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities